Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

178 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
New targeted therapies for anaplastic thyroid cancer.
Antonelli A, Fallahi P, Ulisse S, Ferrari SM, Minuto M, Saraceno G, Santini F, Mazzi V, D'Armiento M, Miccoli P. Antonelli A, et al. Among authors: ulisse s. Anticancer Agents Med Chem. 2012 Jan;12(1):87-93. doi: 10.2174/187152012798764732. Anticancer Agents Med Chem. 2012. PMID: 22043992
High levels of circulating chemokine (C-X-C motif) ligand 11 are associated with euthyroid or subclinically hypothyroid autoimmune thyroiditis and with chemokine (C-X-C motif) ligand 10.
Antonelli A, Ferri C, Ferrari SM, Frascerra S, Ruffilli I, Caponi L, Ulisse S, Miccoli M, Miccoli P, Fallahi P. Antonelli A, et al. Among authors: ulisse s. J Interferon Cytokine Res. 2012 Feb;32(2):74-80. doi: 10.1089/jir.2011.0051. Epub 2011 Dec 14. J Interferon Cytokine Res. 2012. PMID: 22168752 Clinical Trial.
Aurora kinases: new molecular targets in thyroid cancer therapy.
Baldini E, Sorrenti S, D'Armiento E, Prinzi N, Guaitoli E, Favoriti P, Gnessi L, Moretti C, Bianchini M, Alessandrini S, Catania A, De Antoni E, Ulisse S. Baldini E, et al. Among authors: ulisse s. Clin Ter. 2012 Nov;163(6):e457-62. Clin Ter. 2012. PMID: 23306762 Review.
Sorafenib and thyroid cancer.
Fallahi P, Ferrari SM, Santini F, Corrado A, Materazzi G, Ulisse S, Miccoli P, Antonelli A. Fallahi P, et al. Among authors: ulisse s. BioDrugs. 2013 Dec;27(6):615-28. doi: 10.1007/s40259-013-0049-y. BioDrugs. 2013. PMID: 23818056 Review.
CLM29, a multi-target pyrazolopyrimidine derivative, has anti-neoplastic activity in medullary thyroid cancer in vitro and in vivo.
Antonelli A, Bocci G, La Motta C, Ferrari SM, Fallahi P, Corrado A, Fioravanti A, Sartini S, Orlandi P, Piaggi S, Corti A, Materazzi G, Galleri D, Ulisse S, Fontanini G, Danesi R, Da Settimo F, Miccoli P. Antonelli A, et al. Among authors: ulisse s. Mol Cell Endocrinol. 2014 Aug 5;393(1-2):56-64. doi: 10.1016/j.mce.2014.06.002. Epub 2014 Jun 12. Mol Cell Endocrinol. 2014. PMID: 24931161
178 results